Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial

Peter Tugwell, George Wells, Vibeke Strand, Andreas Maetzel, Claire Bombardier, Bruce Crawford, Catherine Dorrier, Ann Thompson, Elizabeth Tindall, Howard Offenberg, Jeffrey Poiley, Joel Rutstein, Frederick Dietz, Alan Brodsky, Robert Harris, Mitchel Lowenstein, Andrew Baldessare, Paul Howard, Marshall Sack, John TesserNathan Wei, Robin Dore, Robert Ettlinger, Larry Anderson, Barry Bockow, Michael Liebling, Paul Romain, Scott Baumgartner, Joel Silverfield, Andrew Chubick, Charles Franklin, Willow Grove, Selwyn Cohen, Gordon Senter, Richard Furie, Sanford Hartman, Robert Levy, David Yocum, Don Cheatum, Sicy Lee, Matthew Heller

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Objective. To examine correlations between clinical improvement as defined by the American College of Rheumatology (ACR) responder analysis and clinical improvement as determined by 4 function and/or health-related quality of life measures, and to estimate the sensitivity and relative efficiency of these measures compared with changes in the tender joint count in patients with rheumatoid arthritis (RA). Methods. A 52-week, multicenter, double-blind controlled trial was conducted to compare treatment with leflunomide (n = 182), methotrexate (n = 180), or placebo (n = 118) in patients with active RA. ACR response rates and improvement in scores on the Health Assessment Questionnaire (HAQ), Problem Elicitation Technique (PET), and medical outcomes survey short form 36 (SF-36) were compared in 438 of the patients. Results. In comparing leflunomide with placebo, the patient global assessment, HAQ disability index, and SF-36 bodily pain scale were most responsive to treatment group differences. The modified HAQ (M-HAQ), PET top 5, SF-36 physical component score, physician global assessment, pain intensity scale, and SF-36 physical functioning scale were more responsive to treatment group differences than was the tender joint count. In comparing methotrexate with placebo, the patient and physician global assessments were most responsive. These 2 measures, as well as the pain intensity scale and the C-reactive protein level, were more responsive to treatment group differences than was the tender joint count, while the SF-36 mental health component score was least responsive. A close correlation between changes in the M-HAQ and HAQ scores indicated that the M-HAQ was similarly responsive to change over time. Improvements in the PET, SF-36 physical component score, bodily pain, and physical functioning scales correlated with the ACR responder status. Conclusion. Both disease-specific and generic measures of function and health-related quality of life detect improvements in RA patients. Using both types of measures for evaluating therapies will identify discernible changes that are important to patients, and will facilitate comparison across different disease states.

Original languageEnglish (US)
Pages (from-to)506-514
Number of pages9
JournalArthritis and Rheumatism
Volume43
Issue number3
DOIs
StatePublished - Mar 2000
Externally publishedYes

Fingerprint

leflunomide
Methotrexate
Rheumatoid Arthritis
Placebos
Quality of Life
ametantrone
Joints
Rheumatology
Pain
Therapeutics
Health
Physicians
Pain Measurement
C-Reactive Protein
Mental Health

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis : Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. / Tugwell, Peter; Wells, George; Strand, Vibeke; Maetzel, Andreas; Bombardier, Claire; Crawford, Bruce; Dorrier, Catherine; Thompson, Ann; Tindall, Elizabeth; Offenberg, Howard; Poiley, Jeffrey; Rutstein, Joel; Dietz, Frederick; Brodsky, Alan; Harris, Robert; Lowenstein, Mitchel; Baldessare, Andrew; Howard, Paul; Sack, Marshall; Tesser, John; Wei, Nathan; Dore, Robin; Ettlinger, Robert; Anderson, Larry; Bockow, Barry; Liebling, Michael; Romain, Paul; Baumgartner, Scott; Silverfield, Joel; Chubick, Andrew; Franklin, Charles; Grove, Willow; Cohen, Selwyn; Senter, Gordon; Furie, Richard; Hartman, Sanford; Levy, Robert; Yocum, David; Cheatum, Don; Lee, Sicy; Heller, Matthew.

In: Arthritis and Rheumatism, Vol. 43, No. 3, 03.2000, p. 506-514.

Research output: Contribution to journalArticle

Tugwell, P, Wells, G, Strand, V, Maetzel, A, Bombardier, C, Crawford, B, Dorrier, C, Thompson, A, Tindall, E, Offenberg, H, Poiley, J, Rutstein, J, Dietz, F, Brodsky, A, Harris, R, Lowenstein, M, Baldessare, A, Howard, P, Sack, M, Tesser, J, Wei, N, Dore, R, Ettlinger, R, Anderson, L, Bockow, B, Liebling, M, Romain, P, Baumgartner, S, Silverfield, J, Chubick, A, Franklin, C, Grove, W, Cohen, S, Senter, G, Furie, R, Hartman, S, Levy, R, Yocum, D, Cheatum, D, Lee, S & Heller, M 2000, 'Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial', Arthritis and Rheumatism, vol. 43, no. 3, pp. 506-514. https://doi.org/10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U
Tugwell, Peter ; Wells, George ; Strand, Vibeke ; Maetzel, Andreas ; Bombardier, Claire ; Crawford, Bruce ; Dorrier, Catherine ; Thompson, Ann ; Tindall, Elizabeth ; Offenberg, Howard ; Poiley, Jeffrey ; Rutstein, Joel ; Dietz, Frederick ; Brodsky, Alan ; Harris, Robert ; Lowenstein, Mitchel ; Baldessare, Andrew ; Howard, Paul ; Sack, Marshall ; Tesser, John ; Wei, Nathan ; Dore, Robin ; Ettlinger, Robert ; Anderson, Larry ; Bockow, Barry ; Liebling, Michael ; Romain, Paul ; Baumgartner, Scott ; Silverfield, Joel ; Chubick, Andrew ; Franklin, Charles ; Grove, Willow ; Cohen, Selwyn ; Senter, Gordon ; Furie, Richard ; Hartman, Sanford ; Levy, Robert ; Yocum, David ; Cheatum, Don ; Lee, Sicy ; Heller, Matthew. / Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis : Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. In: Arthritis and Rheumatism. 2000 ; Vol. 43, No. 3. pp. 506-514.
@article{2088959323bd47f19abf3bff93ebb207,
title = "Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial",
abstract = "Objective. To examine correlations between clinical improvement as defined by the American College of Rheumatology (ACR) responder analysis and clinical improvement as determined by 4 function and/or health-related quality of life measures, and to estimate the sensitivity and relative efficiency of these measures compared with changes in the tender joint count in patients with rheumatoid arthritis (RA). Methods. A 52-week, multicenter, double-blind controlled trial was conducted to compare treatment with leflunomide (n = 182), methotrexate (n = 180), or placebo (n = 118) in patients with active RA. ACR response rates and improvement in scores on the Health Assessment Questionnaire (HAQ), Problem Elicitation Technique (PET), and medical outcomes survey short form 36 (SF-36) were compared in 438 of the patients. Results. In comparing leflunomide with placebo, the patient global assessment, HAQ disability index, and SF-36 bodily pain scale were most responsive to treatment group differences. The modified HAQ (M-HAQ), PET top 5, SF-36 physical component score, physician global assessment, pain intensity scale, and SF-36 physical functioning scale were more responsive to treatment group differences than was the tender joint count. In comparing methotrexate with placebo, the patient and physician global assessments were most responsive. These 2 measures, as well as the pain intensity scale and the C-reactive protein level, were more responsive to treatment group differences than was the tender joint count, while the SF-36 mental health component score was least responsive. A close correlation between changes in the M-HAQ and HAQ scores indicated that the M-HAQ was similarly responsive to change over time. Improvements in the PET, SF-36 physical component score, bodily pain, and physical functioning scales correlated with the ACR responder status. Conclusion. Both disease-specific and generic measures of function and health-related quality of life detect improvements in RA patients. Using both types of measures for evaluating therapies will identify discernible changes that are important to patients, and will facilitate comparison across different disease states.",
author = "Peter Tugwell and George Wells and Vibeke Strand and Andreas Maetzel and Claire Bombardier and Bruce Crawford and Catherine Dorrier and Ann Thompson and Elizabeth Tindall and Howard Offenberg and Jeffrey Poiley and Joel Rutstein and Frederick Dietz and Alan Brodsky and Robert Harris and Mitchel Lowenstein and Andrew Baldessare and Paul Howard and Marshall Sack and John Tesser and Nathan Wei and Robin Dore and Robert Ettlinger and Larry Anderson and Barry Bockow and Michael Liebling and Paul Romain and Scott Baumgartner and Joel Silverfield and Andrew Chubick and Charles Franklin and Willow Grove and Selwyn Cohen and Gordon Senter and Richard Furie and Sanford Hartman and Robert Levy and David Yocum and Don Cheatum and Sicy Lee and Matthew Heller",
year = "2000",
month = "3",
doi = "10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U",
language = "English (US)",
volume = "43",
pages = "506--514",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Clinical improvement as reflected in measures of function and health- related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis

T2 - Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial

AU - Tugwell, Peter

AU - Wells, George

AU - Strand, Vibeke

AU - Maetzel, Andreas

AU - Bombardier, Claire

AU - Crawford, Bruce

AU - Dorrier, Catherine

AU - Thompson, Ann

AU - Tindall, Elizabeth

AU - Offenberg, Howard

AU - Poiley, Jeffrey

AU - Rutstein, Joel

AU - Dietz, Frederick

AU - Brodsky, Alan

AU - Harris, Robert

AU - Lowenstein, Mitchel

AU - Baldessare, Andrew

AU - Howard, Paul

AU - Sack, Marshall

AU - Tesser, John

AU - Wei, Nathan

AU - Dore, Robin

AU - Ettlinger, Robert

AU - Anderson, Larry

AU - Bockow, Barry

AU - Liebling, Michael

AU - Romain, Paul

AU - Baumgartner, Scott

AU - Silverfield, Joel

AU - Chubick, Andrew

AU - Franklin, Charles

AU - Grove, Willow

AU - Cohen, Selwyn

AU - Senter, Gordon

AU - Furie, Richard

AU - Hartman, Sanford

AU - Levy, Robert

AU - Yocum, David

AU - Cheatum, Don

AU - Lee, Sicy

AU - Heller, Matthew

PY - 2000/3

Y1 - 2000/3

N2 - Objective. To examine correlations between clinical improvement as defined by the American College of Rheumatology (ACR) responder analysis and clinical improvement as determined by 4 function and/or health-related quality of life measures, and to estimate the sensitivity and relative efficiency of these measures compared with changes in the tender joint count in patients with rheumatoid arthritis (RA). Methods. A 52-week, multicenter, double-blind controlled trial was conducted to compare treatment with leflunomide (n = 182), methotrexate (n = 180), or placebo (n = 118) in patients with active RA. ACR response rates and improvement in scores on the Health Assessment Questionnaire (HAQ), Problem Elicitation Technique (PET), and medical outcomes survey short form 36 (SF-36) were compared in 438 of the patients. Results. In comparing leflunomide with placebo, the patient global assessment, HAQ disability index, and SF-36 bodily pain scale were most responsive to treatment group differences. The modified HAQ (M-HAQ), PET top 5, SF-36 physical component score, physician global assessment, pain intensity scale, and SF-36 physical functioning scale were more responsive to treatment group differences than was the tender joint count. In comparing methotrexate with placebo, the patient and physician global assessments were most responsive. These 2 measures, as well as the pain intensity scale and the C-reactive protein level, were more responsive to treatment group differences than was the tender joint count, while the SF-36 mental health component score was least responsive. A close correlation between changes in the M-HAQ and HAQ scores indicated that the M-HAQ was similarly responsive to change over time. Improvements in the PET, SF-36 physical component score, bodily pain, and physical functioning scales correlated with the ACR responder status. Conclusion. Both disease-specific and generic measures of function and health-related quality of life detect improvements in RA patients. Using both types of measures for evaluating therapies will identify discernible changes that are important to patients, and will facilitate comparison across different disease states.

AB - Objective. To examine correlations between clinical improvement as defined by the American College of Rheumatology (ACR) responder analysis and clinical improvement as determined by 4 function and/or health-related quality of life measures, and to estimate the sensitivity and relative efficiency of these measures compared with changes in the tender joint count in patients with rheumatoid arthritis (RA). Methods. A 52-week, multicenter, double-blind controlled trial was conducted to compare treatment with leflunomide (n = 182), methotrexate (n = 180), or placebo (n = 118) in patients with active RA. ACR response rates and improvement in scores on the Health Assessment Questionnaire (HAQ), Problem Elicitation Technique (PET), and medical outcomes survey short form 36 (SF-36) were compared in 438 of the patients. Results. In comparing leflunomide with placebo, the patient global assessment, HAQ disability index, and SF-36 bodily pain scale were most responsive to treatment group differences. The modified HAQ (M-HAQ), PET top 5, SF-36 physical component score, physician global assessment, pain intensity scale, and SF-36 physical functioning scale were more responsive to treatment group differences than was the tender joint count. In comparing methotrexate with placebo, the patient and physician global assessments were most responsive. These 2 measures, as well as the pain intensity scale and the C-reactive protein level, were more responsive to treatment group differences than was the tender joint count, while the SF-36 mental health component score was least responsive. A close correlation between changes in the M-HAQ and HAQ scores indicated that the M-HAQ was similarly responsive to change over time. Improvements in the PET, SF-36 physical component score, bodily pain, and physical functioning scales correlated with the ACR responder status. Conclusion. Both disease-specific and generic measures of function and health-related quality of life detect improvements in RA patients. Using both types of measures for evaluating therapies will identify discernible changes that are important to patients, and will facilitate comparison across different disease states.

UR - http://www.scopus.com/inward/record.url?scp=0034039972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034039972&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U

DO - 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U

M3 - Article

C2 - 10728742

AN - SCOPUS:0034039972

VL - 43

SP - 506

EP - 514

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 3

ER -